Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy®...
Idorsia Ltd announced the publication of "Aprocitentan for Blood Pressure Reduction in Black Patients” in the April edition of Hypertensio...
Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases, announced data from its herp...
Science 37, a leader in enhancing patient access to clinical trials, announced the successful completion of its second FDA inspection, reaffirming the qual...
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform&tra...
Impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®...
CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of proteinuria ...
Halozyme Therapeutics, Inc.announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) mark...
NeuroSense Therapeutics, a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, announced t...
Keymed Biosciences Inc. announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its ...
Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendoc...
NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company th...
Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective e...
Genentech, a member of the Roche Group, announced that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...
© 2025 Biopharma Boardroom. All Rights Reserved.
